Introduction {#s1}
============

The myelodysplastic syndromes (MDSs) are clonal stem cell disorders characterized by ineffective hematopoiesis, morphologic dysplasia, and a variable risk of progression to acute myeloid leukemia (AML) ([@bib11]). Monosomy 7 (−7) and deletions affecting the long arm of chromosome 7 \[del(7q)\] are highly prevalent acquired cytogenetic abnormalities in de novo and in therapy-related MDS and AML (t-MDS/t-AML) ([@bib44]). The proportion of −7/del(7q) cells is markedly increased in the hematopoietic stem cell (HSC) and progenitor compartments of MDS patients relative to T and B lymphocytes ([@bib21]; [@bib1]; [@bib6]; [@bib53]; [@bib11]). Recent studies demonstrating quantitative changes in the frequencies of phenotypic primitive long-term HSCs, common myeloid progenitors (CMPs), and granulocyte-monocyte progenitors (GMPs) in MDS patients with −7/del(7q) further support diverse effects on hematopoiesis ([@bib53]; [@bib35]).

Multiple studies of MDS and AML specimens with interstitial deletions on 7q have implicated three putative commonly deleted segments (CDSs) at chromosome bands 7q22, 7q34, and 7q35-36 ([Figure 1A](#fig1){ref-type="fig"}) ([@bib20]; [@bib24]; [@bib13]; [@bib26]; [@bib49]; [@bib19]; [@bib28]; [@bib17]). Of these intervals, 7q22 is deleted most frequently in cases of MDS or AML with a del(7q) ([@bib24]). Targeted sequencing of candidate myeloid tumor suppressor genes (TSGs) located within a 2.5 Mb 7q22 CDS delineated by [@bib24], and recent comprehensive genomic analyses of clinical specimens strongly implicate a haploinsufficient role of 7q22 deletions in leukemogenesis ([@bib22]; [@bib13]; [@bib26]; [@bib49]; [@bib10]; [@bib19]; [@bib28]; [@bib17]). Consistent with this proposed mechanism, biallelic inactivation of any 7q gene is rare in MDS patients with −7/del(7q). For example, whole exome sequencing of 68 myeloid malignancies characterized by −7/del(7q) uncovered recurrent mutations in only *EZH2* (located at 7q36; n = 4) and *LUC7L2* (at 7q34; n = 3). Biallelic inactivation of these genes and of *CUX1* (located at 7q22) was observed in a small cohort of patients with 7q isodisomy ([@bib17]). *SAMD9L*, *RASA4*, *DOCK4*, and *MLL3* are other 7q genes that have been implicated as contributing to leukemogenesis by haploinsufficiency or epigenetic transcriptional repression ([Figure 1A](#fig1){ref-type="fig"}) ([@bib2]; [@bib57]; [@bib31]; [@bib9]; [@bib37]). Here, we demonstrate hematopoietic abnormalities in mice with a germ line deletion of a contiguous CDS of chromosome band 5A3 (*5A3*^*+/del*^) syntenic to a 2.5 Mb 7q22 CDS delineated by [@bib24] that support a mechanistic role of 7q22 deletions in MDS pathogenesis.10.7554/eLife.07839.003Figure 1.A heterozygous *5A3* deletion corresponding to human *7q22* perturbs steady-state hematopoiesis.(**A**) Top, candidate 7q myeloid tumor suppressor genes described previously ([@bib2]; [@bib12]; [@bib33]; [@bib57]; [@bib28]; [@bib9]; [@bib17]; [@bib37]) appear above the diagram of chromosome 7q while commonly deleted segments (CDSs) within 7q22, 7q34, and 7q35-36 identified by different research groups ([@bib20]; [@bib24]; [@bib13]; [@bib26]; [@bib49]; [@bib19]; [@bib28]; [@bib17]) are depicted by brackets immediately below it. Middle, dotted lines demarcate the segments of mouse chromosome 5A3 corresponding to the human 7q22 CDS targeted in this study. Bottom, expressing Cre recombinase in embryonic stem (ES) cells doubly targeted with LoxP sequences within the *Fbxl13* and *Srpk2* genes excised a 2-Mb interval. Gene order is based on the Ensembl database and is not drawn to scale. (**B**) Total numbers of bone marrow (BM) cells from 2 femurs and 2 tibiae in *5A3*^*+/del*^ mice and wild-type (WT) littermates at 8--12 weeks of age. (**C**, **D**) Spleen (**C**) and thymus (**D**) weights in *5A3*^*+/del*^ mice and WT littermates at 8--12 weeks of age. (**E**, **F**) Percent contributions (**E**) and frequencies (**F**) of cells with high (CD150^hi^ HSC), low (CD150^lo^ HSC), and absent CD150 expression (CD150^neg^ MPP) within the K^+^L^−^S^+^CD41^−^CD48^−^ compartment of WT and *5A3*^*+/del*^ mice at 8--12 weeks of age (n = 6 of each genotype). (**G**) Percent contribution of common myeloid progenitor (CMP), granulocyte-monocyte progenitor (GMP), and megakaryocyte erythroid progenitors (MEP) within the Lin^−^Sca1^+^c-kit^+^ compartment of *5A3*^*+/del*^ mice and WT littermates. (**H**) Frequencies of CMP, GMP, and MEP in WT and *5A3*^*+/del*^ BM. The error bars indicate S.E.M. with significant differences between WT and *5A3*^*+/del*^ mice designated by asterisks as follows: \*p \< 0.05, \*\*p \< 0.01.**DOI:** [http://dx.doi.org/10.7554/eLife.07839.003](10.7554/eLife.07839.003)10.7554/eLife.07839.004Figure 1---figure supplement 1.Gating strategy for hematopoietic stem and progenitor populations.(**A**) Gating strategy for CD150^hi^-HSC, CD150^lo^-HSC, and CD150^neg^-MPP. K^+^L^−^S^+^CD41^−^CD48^−^ cells were separated based on CD150 expression into CD150^hi^, CD150^lo^, and CD150^neg^ populations. Representative plots from WT (top) and *5A3*^*+/del*^ (bottom) mice are shown. (**B**) Gating strategy for CMP, GMP, and MEP. K^+^L^−^S^−^ cells were subdivided by CD34 and FcγR expression into CMP (CD34^+^FcγR^lo^), GMP (CD34^+^FcγR^hi^), and MEP (CD34^−^FcγR^lo^). Representative plots from WT (top) and *5A3*^*+/del*^ (bottom) mice are shown. (**C**) Gating strategy for common lymphoid progenitor (CLP). Lin^−^ cells were gated for CLP (Flk2^+^IL7Rα^+^). (**D**) Percent contribution of CLP within the Lin^−^ compartment of WT (n = 6) and *5A3*^*+/del*^ (n = 6) mice. (**E**) Frequencies of CLP in WT (n = 6) and *5A3*^*+/del*^ (n = 6) BM. For CLP staining experiments, data shown are mean values ±SEM of results from three independent experiments. For gating strategy figures, the numbers are expressed as percentages of the parental gates.**DOI:** [http://dx.doi.org/10.7554/eLife.07839.004](10.7554/eLife.07839.004)

Results and discussion {#s2}
======================

Abnormal differentiation and repopulation of *5A3*^*+/del*^ stem and progenitor cells {#s2-1}
-------------------------------------------------------------------------------------

We generated mice carrying a 2 Mb germ line *5A3* deletion that removes 13 genes syntenic to a human 7q22 CDS ([Figure 1A](#fig1){ref-type="fig"}) ([@bib54]). *5A3*^*+/del*^ mice are smaller than wild-type (WT) littermates, and homozygous deletion of the *5A3* region causes embryonic lethality before 10.5 dpc (data not shown). Total nucleated bone marrow (BM) cell counts as well as spleen and thymus weights are reduced in mutant animals ([Figure 1B--D](#fig1){ref-type="fig"}), which maintain normal peripheral blood cell counts.

Differential expression of CD150 distinguishes HSC populations with different self-renewal, differentiation, and repopulating potentials. Specifically, HSCs, with a surface c-kit^+^, lineage^−^, Sca-1^+^ (KLS), and CD150^hi^ (CD150^hi^ HSC) immunophenotype possess potent self-renewal capacity, are predisposed to myeloid differentiation and expand upon aging ([@bib23]; [@bib3]; [@bib16]). Strikingly, the proportion of CD150^hi^ HSCs is increased in *5A3*^*+/del*^ BM with a corresponding decrease in the percentage of CD150 negative multi-potent progenitors (CD150^neg^ MPP) ([Figure 1E](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1A](#fig1s1){ref-type="fig"}). This results in a normal frequency of CD150^hi^ HSCs in *5A3*^*+/del*^ mice, despite an overall reduction in the size of the stem/progenitor compartment ([Figure 1F](#fig1){ref-type="fig"}). The proportion of CMPs is elevated in *5A3*^*+/del*^ mice and the frequency of GMPs is decreased ([Figure 1G,H](#fig1){ref-type="fig"}, [Figure 1---figure supplement 1B](#fig1s1){ref-type="fig"}), which is consistent with changes in these populations in MDS patients ([@bib53]; [@bib35]). Thus, the *5A3* deletion perturbs HSC and myeloid progenitor populations. By contrast, the proportions and frequencies of common lymphoid progenitors are similar in WT and *5A3*^*+/del*^ mice ([Figure 1---figure supplement 1C--E](#fig1s1){ref-type="fig"}).

We mixed donor *5A3*^*+/del*^ or WT BM cells with WT BM at ratios of 1:1 and 1:2 and transplanted them into irradiated recipients. Whereas *5A3* mutant BM had markedly reduced lymphoid repopulating capacity, these cells efficiently contributed to the c-kit^+^lin^−^Sca-1^+^ (KLS) compartment ([Figure 2A,B](#fig2){ref-type="fig"}). To investigate if the altered repopulating potential of *5A3*^*+/del*^ BM is intrinsic to CD150^hi^ HSC, we injected 15 of these cells into lethally irradiated recipients with WT BM competitors. Similar to whole BM, CD150^hi^ HSC from *5A3*^*+/del*^ mice exhibited reduced overall repopulation potential due to defective lymphoid reconstitution ([Figure 2C--F](#fig2){ref-type="fig"}). Importantly, however, *5A3*^*+/del*^ HSC efficiently reconstituted KLS and myeloid compartments in both primary and secondary recipients ([Figure 2E,F](#fig2){ref-type="fig"}). *5A3*^*+/del*^ CD150^hi^ HSC exhibited markedly reduced lymphoid repopulating potential in WT and *5A3*^*+/del*^ recipients, whereas WT cells restored lymphoid repopulation in *5A3*^*+/del*^ hosts almost as well as in WT recipients, demonstrating that the repopulation defects in *5A3*^*+/del*^ CD150^hi^ HSCs are cell intrinsic ([Figure 2C--F](#fig2){ref-type="fig"}).10.7554/eLife.07839.005Figure 2.Defective repopulating potential of *5A3*^*+/del*^ BM and CD150^hi^ HSC.(**A**, **B**) BM cells from WT or *5A3*^*+/del*^ mice (n = 9 per genotype) were mixed at ratios of 1:1 and 1:2 with WT competitor cells and transplanted into 2--3 irradiated WT recipients. Percent contribution to the K^+^L^−^S^+^ (KLS), K^+^L^−^S^−^ (MP), myeloid, B and T cell lineages in the BM of recipient mice 6 months after primary (**A**) and secondary (**B**) transplants are shown. (**C**) Leukocyte chimerism after competitive transplantation of 15 *5A3*^*+/del*^ or WT CD150^hi^ HSC into WT or mutant recipients (n = 12 for WT hematopoietic stem cell (HSC) in WT recipients; n = 12 for *5A3*^*+/del*^ HSC in WT recipients; n = 8 for WT HSC in *5A3*^*+/del*^ recipients; n = 9 for *5A3*^*+/del*^ HSC in *5A3*^*+/del*^ recipients). (**D**--**F**) Relative proportions of donor-derived B, T, and myeloid cells in the blood of recipient mice 6 months after transplantation (**D**). Percent contribution to the K^+^L^−^S^+^ (KLS), K^+^L^−^S^−^ (MP), myeloid, B and T cell lineages in the BM of recipient mice 6 months after primary (**E**) and secondary (**F**) transplants. Data shown are mean values ±SEM of results from four independent experiments. (**G**--**I**) 100 CD150^hi^ HSC, CD150^lo^ HSC, and CD150^neg^ MPP from 8- to 12-week-old *5A3*^*+/del*^ mice and their WT littermates were plated into methylcellulose medium supplemented with cytokines (n = 6 for each genotype). The total number of colonies (**G**) and the average number of cells per colony (**H**, **I**) were assessed after 7 days. Dots represent individual mice, and the horizontal lines indicate median values. Data shown are mean values ±SEM of results from three independent experiments with significant differences between WT and *5A3*^*+/del*^ mice designated by asterisks as follows: \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001.**DOI:** [http://dx.doi.org/10.7554/eLife.07839.005](10.7554/eLife.07839.005)10.7554/eLife.07839.006Figure 2---figure supplement 1.Proliferation and divisional kinetics of *5A3*^*+/del*^ HSCs.(**A**) BrdU labeling frequencies of K^+^L^−^S^+^ and K^+^L^−^S^−^ cells from WT and *5A3*^*+/del*^ mice taken 24 hr after intraperitoneal injection of BrdU. (**B**) HSCs were labeled with EZ-Link Sulfo-NHS-LC-LC-biotin (biotin) in vivo, and the in vivo proliferative behavior of HSCs was tracked by dilution of the biotin label caused by cell division. Biotin intensities on CD150^hi^ HSC, CD150^lo^ HSC, and CD150^neg^ MPP taken 15 min and 6 days after intravenous injection of biotin (representative plots from one of 3 mice in each group). Following 6 days of chase, the reduction in biotin label intensity is similar in WT and *5A3*^*+/del*^ CD150^hi^ HSC, CD150^lo^ HSC, and CD150^neg^ MPP.**DOI:** [http://dx.doi.org/10.7554/eLife.07839.006](10.7554/eLife.07839.006)

*WT* and *5A3*^*+/del*^ HSCs generated similar numbers of myeloid colonies in methylcellulose cultures supplemented with cytokines; however, colonies grown from *5A3*^*+/del*^ CD150^hi^ HSC contained significantly fewer cells ([Figure 2G,H](#fig2){ref-type="fig"}). By contrast, *5A3*^*+/del*^ CD150^neg^ MPP showed a 1.4-fold increase in colony forming activity but a similar number of cells per colony as WT MPP ([Figure 2G,I](#fig2){ref-type="fig"}). In vivo labeling experiments revealed similar rates of BrdU incorporation, cell division, and apoptosis in WT and *5A3*^*+/del*^ K^+^L^−^S^+^ and myeloid progenitor (MP) cells ([Figure 2---figure supplement 1A,B](#fig2s1){ref-type="fig"} and data not shown) ([@bib34]).

Effects of aging on *5A3*^*+/del*^ HSC and interaction with *Gata2* haploinsufficiency {#s2-2}
--------------------------------------------------------------------------------------

Physiologic aging is characterized by impaired HSC repopulating potential, diminished lymphoid differentiation, the dominance of CD150^hi^ HSCs that are skewed toward myeloid differentiation and a markedly increased risk of MDS ([@bib3]; [@bib4]). Similarly, the abnormal distribution of HSCs is exacerbated in 24- to 30-month-old *5A3*^*+/del*^ mice ([Figure 3A,B](#fig3){ref-type="fig"}). Consistent with data from younger mice ([Figure 2A--F](#fig2){ref-type="fig"}), aged *5A3* mutant BM displayed markedly reduced lymphoid repopulating potential, but efficiently contributed to myeloid reconstitution ([Figure 3C,D](#fig3){ref-type="fig"}). Old *5A3*^*+/del*^ BM cells also repopulated the KLS compartment significantly better than WT BM in recipients analyzed 4 months after transplantation, and *5A3*^*+/del*^ cells exhibited a twofold increase in contribution to the KLS and MP populations upon serial transplantation ([Figure 3C,D](#fig3){ref-type="fig"}). Despite these HSC abnormalities, *5A3*^*+/del*^ *mice* have a normal lifespan, and the underlying causes of death are similar to WT littermates (data not shown).10.7554/eLife.07839.007Figure 3.Effects of aging and *Gata2* inactivation on *5A3*^*+/del*^ hematopoietic cells.(**A** and **B**) Percent contributions (**A**) and frequencies (**B**) of CD150^hi^ HSC, CD150^lo^ HSC, and CD150^neg^ MPP within the K^+^L^−^S^+^CD41^−^CD48^−^ compartment in *5A3*^*+/del*^ mice (n = 12) and their WT littermates (n = 11) at 24--30 months of age. (**C** and **D**) Competitive transplantation of BM cells from 24- to 30-month-old WT or *5A3*^*+/del*^ mice. Percent donor contribution of *5A3*^*+/del*^ cells to K^+^L^−^S^+^ (KLS), K^+^L^−^S^−^ (MP), myeloid, B cell, and T cell populations in the BM of recipient mice 4 months after primary (**C**) and secondary (**D**) competitive transplantation (n = 5 donors and 10 recipients of each genotype). Data shown are mean values ±SEM of results from two independent experiments. (**E**) Total numbers of BM cells from 2 femurs and 2 tibiae in *5A3*^*+/del*^ mice, *Gata2*^*+/−*^ mice, compound *Gata2*^*+/−*^; *5A3*^*+/del*^ mice and WT littermates at 8--12 weeks of age. (**F**) Spleen weights in *5A3*^*+/del*^ mice, *Gata2*^*+/−*^ mice, compound *Gata2*^*+/−*^; *5A3*^*+/del*^ mice, and WT littermates at 8--12 weeks of age. (**G**) Percent contributions of cells with high (CD150^hi^ HSC), low (CD150^lo^ HSC), and absent CD150 expression (CD150^neg^ MPP) within the K^+^L^−^S^+^CD41^−^CD48^−^ compartment of WT, *5A3*^*+/del*^, *Gata2*^*+/−*^, and compound *Gata2*^*+/−*^; *5A3*^*+/del*^ mice at 8--12 weeks of age (n = 5 of each genotype). (**H**) BM cells from WT, *5A3*^*+/del*^, *Gata2*^*+/−*^ or compound *Gata2*^*+/−*^; *5A3*^*+/del*^ mice (n = 5 of each genotype) were each mixed at ratios of 1:1 with WT competitor cells and transplanted into two irradiated WT recipients. Percent contribution to the K^+^L^−^S^+^ (KLS), K^+^L^−^S^−^ (MP), myeloid, B and T cell lineages in the BM of recipient mice 6 months after primary transplants. Data shown are mean values ±SEM from five independent experiments with significant differences designed by asterisks as follows: \*p \< 0.05, \*\*p \< 0.01, \*\*\*p \< 0.001. The enhanced repopulating ability of compound *Gata2*^*+/−*^; *5A3*^*+/del*^ vs *Gata2* singly mutant HSC achieved borderline statistical significance in three myeloid populations (KLS (p = 0.09), MP (p = 0.09), and myeloid cells (p = 0.12)).**DOI:** [http://dx.doi.org/10.7554/eLife.07839.007](10.7554/eLife.07839.007)

*GATA2* mutations cause familial MDS, which is frequently characterized by −7/del(7q) ([@bib15]; [@bib8]; [@bib36]). We generated *Gata2*^*+/−*^; *5A3*^*+/del*^ mice, quantified HSC and progenitor populations, and performed competitive repopulation experiments. Like *5A3*^*+/del*^ mutant mice, *Gata2*^*+/−*^; *5A3*^*+/del*^ mice have reduced BM cellularity and spleen weights ([Figure 3E,F](#fig3){ref-type="fig"}), and the CD150^hi^ HSC bias is augmented by concomitant *Gata2* deletion ([Figure 3G](#fig3){ref-type="fig"}). Whereas lymphoid reconstitution is similarly impaired in *5A3*^*+/del*^ and compound mutant mice, the *5A3* deletion partially rescues the repopulating deficit of *Gata2*^*+/−*^ BM in the KLS, MP, and myeloid compartments ([Figure 3H](#fig3){ref-type="fig"}) ([@bib41]). These data suggest that the 7q22 CDS contributes to transformation in familial MDS by impairing lymphoid differentiation while also modestly enhancing the growth of *GATA2* mutant HSC and their myeloid progeny.

Changes in gene expression and metabolic activities in *5A3*^*+/del*^ hematopoietic cells {#s2-3}
-----------------------------------------------------------------------------------------

Transcriptome (RNA-Seq) and TaqMan quantitative real-time PCR analyses revealed a ∼50% reduction in the expression of multiple genes and of the long intergenic non-coding RNA 503142E22Rik within the *5A3* interval in mutant HSC and MPP ([Figure 4A,B](#fig4){ref-type="fig"}). Gene Set Enrichment Analysis (GSEA) of the RNA-Seq data from *5A3*^*+/del*^ HSCs further demonstrated reduced expression of multiple gene sets related to oxidative phosphorylation (OXPHOS) that are similarly down-regulated in the early stages of human therapy-induced MDS and AML ([Figure 4C](#fig4){ref-type="fig"}) ([@bib30]; [@bib25]). OXPHOS is the metabolic pathway used by cells to generate adenosine triphosphate (ATP). OXPHOS is regulated by mitochondrial membrane potential, and defects in this metabolic pathway can increase levels of reactive oxygen species (ROS). However, sorted WT and *5A3*^*+/del*^ HSC and MPP showed similar ATP levels ([Figure 4D](#fig4){ref-type="fig"}). Membrane potential and intracellular ROS levels were also similar in HSC and MPP from young mice, but ROS levels were increased by ∼50% in the HSC and MPP of aged *5A3*^*+/del*^ mice ([Figure 4E,F](#fig4){ref-type="fig"}). Elevated ROS levels in HSCs correlate with reduced self-renewal capacity, impaired multi-lineage repopulating ability, and myeloid-biased differentiation ([@bib18]). ROS levels are also increased in t-MDS/AML BM ([@bib39]; [@bib25]).10.7554/eLife.07839.008Figure 4.Changes in gene expression and oxidative phosphorylation in *5A3*^*+/del*^ HSC and MP.(**A**) Relative mRNA abundances for genes within the deleted *5A3* interval expressed at detectable levels in sorted HSC populations were determined by TaqMan reverse transcriptase PCR (n = 3 per genotype). (**B**) Expression levels of genes located within and flanking the deleted interval measured by RNA-Seq in sorted CD150^hi^ HSC and CD150^lo^ HSC from 5 mice of each genotype. Each column presents data from an individual mouse, and genes within the *5A3* deleted region are delimited with a black box. Three non-coding RNAs (6030443J06Rik, AC112688.1 and 5031425E22Rik) are located within the *5A3* deletion. Two of these (6030443J06Rik and AC112688.1) are expressed at extremely low levels in HSC, and the other (5031425E22Rik) showed ∼50% lower expression in *5A3*^*+/del*^ HSC. 5031425E22Rik is homologous to the human *KMT2E* (a.k.a. *MLL5*) antisense RNA1. Expression levels of the flanking *Fbxl13* and *Srpk2* genes are modestly up-regulated in *5A3*^*+/del*^ HSC, which is consistent with the targeting strategy used to generate the segmental deletion. (**C**) Gene Set Enrichment Analysis of *5A3*^*+/del*^ CD150^hi^ HSCs revealed negative enrichment for genes associated with oxidative phosphorylation (OXPHOS). False discovery rate (FDR) q-val, nominal p-value (NOM p-value), and normalized enrichment scores (NESs) are indicated. (**D**) ATP levels in HSC and MPP from 8- to 12-week-old WT (n = 6) and *5A3*^*+/del*^ (n = 5) mice. Data shown are mean values ±SEM of results from two independent experiments. (**E**) Fold change in the mean MitoTracker Orange fluorescence levels in *5A3*^*+/del*^ cells normalized to values in WT cells analyzed in the same experiment. (**F**) Fold change in the mean fluorescence level (MFI) of *5A3*^*+/del*^ cells that are CellROX Orange positive normalized to values in WT cells analyzed in the same experiment. For the MitoTracker and CellROX experiments, n = 13 for WT and n = 12 for *5A3*^*+/del*^ young mice, three independent experiments; n = 5 for WT and n = 6 for *5A3*^*+/del*^ aged mice, two independent experiments. Data shown are mean values ±SEM of results from independent experiments. (**G** and **H**) Oxygen consumption rate (OCR) was assessed basally and in response to the mitochondrial inhibitors oligomycin (oligo), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP), and antimycin A and rotenone (A/R) for (**G**) KLS and (**H**) MP cells. Data are shown as mean ±SEM of n = 5 mice of each genotype from two independent experiments.**DOI:** [http://dx.doi.org/10.7554/eLife.07839.008](10.7554/eLife.07839.008)

Down-regulation of OXPHOS genes is expected to reduce mitochondrial respiration in HSC ([@bib52]). We attempted to directly measure oxygen consumption rates (OCRs) in CD150^hi^ and CD150^lo^ HSC but could not obtain reproducible results due to limiting cell numbers. We therefore compared the OCRs of KLS, MP, B, and T cells isolated from 1-year-old WT and *5A3*^*+/del*^ mice. *5A3*^*+/del*^ KLS cells showed a similar basal OCR as their WT counterparts, but a slightly lower maximal respiratory capacity that did not reach statistical significance (p = 0.2562) ([Figure 4G](#fig4){ref-type="fig"}). *5A3*^*+/del*^ MPs surprisingly showed a significantly higher basal respiration and maximal respiratory capacity in comparison to WT cells, supporting an overall increase in energy consumption ([Figure 4H](#fig4){ref-type="fig"}). Meanwhile, mature *5A3*^*+/del*^ B and T cells have similar mitochondrial stress profiles as WT cells. We conclude that global changes in OXPHOS gene expression exert a modest impact on cellular metabolism in aged *5A3* mutant HSC and progenitors. Interestingly, treatment with N-acetyl-L-cysteine (NAC) did not reverse the hematopoietic abnormalities in young *5A3*^*+/del*^ mice (data not shown), suggesting that they are a direct consequence of the *5A3* deletion and are not secondary to ROS production.

Segmental deletions are among the most frequent genetic alterations in human cancer, and simultaneous loss of multiple haploinsufficient TSGs that individually have minimal phenotypic consequences appears to underlie the growth advantage conferred by most of these chromosomal losses ([@bib46]). We show that a haploinsufficient deletion in mice that models loss of a human 7q22 CDS causes hematopoietic abnormalities that include a myeloid lineage output bias, impaired lymphoid repopulating potential, and a pronounced age-associated expansion of HSC and MPs. These functional abnormalities support a role of 7q22 deletions in MDS pathogenesis. The seven genes within the deleted *5A3* segment that are expressed in HSC encode proteins that regulate diverse cellular processes including transcription (*Mll5* and *Dnajc2*), mitochondrial quality control (*Pmpcb, Armc10*), protein degradation (*Psmc2*), biosynthesis of *N*-acylethanolamines (*Napepld*), and DNA replication (*Orc5*) ([@bib27]; [@bib38]; [@bib14]; [@bib42]; [@bib40]; [@bib32]; [@bib51]; [@bib58]; [@bib43]). Given this, it is likely that the haploinsufficiency for multiple interacting genes leads to altered hematopoietic differentiation and function in *5A3*^*+/del*^ mice. Similar to the *5A3*^*+/del*^ mice described here, other mutations found in MDS patients perturb hematopoiesis, but do not consistently induce hematologic disease in the absence of cooperating mutations ([@bib7]). This is not unexpected given the advanced age of most MDS patients and the presence of multiple genetic lesions in diseased BM. The *5A3*^*+/del*^ mice reported here thus provide a novel resource for addressing how this common deletion cooperates with other mutations to drive myeloid transformation, progression to AML, and drug resistance.

Materials and methods {#s3}
=====================

Mice {#s3-1}
----

We expressed Cre recombinase in embryonic stem cells containing *LoxP* sites and hypoxanthine phosphoribosyl transferase (HPRT) sequences flanking the *Fbxl13* and *Srpk2* genes ([@bib54]) and analyzed clones that grew in hypoxanthine-aminopterin-thymidine (HAT) medium to identify the desired 2 Mb deletion. *5A3*^*del/+*^ mice were generated by standard blastocyst injection followed by mating coat color chimeras and were backcrossed for at least 10 generations onto a C57BL/6J background. *Gata2*^*+/−*^ mice were a generous gift from Dr Stuart Orkin (Harvard Medical School) ([@bib50]). Study mice were housed in a specific pathogen-free facility at the University of California San Francisco, and all animal experiments were conducted under protocols approved by the Institutional Animal Care and Use Committee. Genotyping and disease monitoring were performed as previously described ([@bib54]).

Flow cytometry {#s3-2}
--------------

BM cells flushed from tibias and femurs were subjected to ammonium-chloride potassium red cell lysis before staining with antibodies. For experiments requiring cell sorting, the spinal cord, flat bone of the pelvis, humerus, and sternum of the mice were also crushed and lysed. Low-density mononuclear cells were separated using a HISTOPAQUE-1119 gradient (Sigma--Aldrich, St. Louis, MO, United States). For identification and sorting of CD150^hi^-HSC, CD150^lo^-HSC, and CD150^neg^-MPP, cells were pre-incubated with purified CD16/32 (2.4G2), followed by staining with a lineage cocktail of PE-conjugated antibodies including B220 (RA3-6B2), CD8 (53-6.7), Gr-1 (RB6-8C5), CD3 (17A2), Ter119 (TER-119), CD41 (MWReg30), and CD48 (HM48-1), as well as PE-Cy7 c-kit (2B8), PacBlue Sca-1 (E13-161.7), and APC CD150 (TC15-12F12.2) from BioLegend (San Diego, CA, United States). For experiments requiring cell sorting, cells expressing c-kit were enriched by magnetic cell sorting by staining with mouse CD117 microbeads and positively selected on the MS columns (Miltenyi Biotec, Germany) according to manufacturer\'s protocol before antibody staining. Cells were classified as CD150^hi^-HSC, CD150^lo^-HSC, or CD150^neg^-MPP based in levels of CD150 expression.

Percent contribution of common myeloid progenitor (CMP), granulocyte-monocyte progenitor (GMP), and megakaryocyte erythroid progenitors (MEP) within the Lin−Sca1+c-kit+ compartment of 5A3+/del mice and WT littermates. CMP, GMP, and megakaryocyte erythroid progenitors (MEP) populations were identified by flow cytometry after staining with a lineage cocktail of PE-conjugated antibodies including B220 (RA3-6B2), CD8 (53-6.7), Gr-1 (RB6-8C5), CD3 (17A2), and Ter119 (TER-119), as well as APC-750 c-kit (2B8), PacBlue Sca-1 (E13-161.7), Alexa Fluor 647 CD16/32 (93), biotin CD34 (MEC14.7), and a streptavidin PE-Cy7 conjugate (BioLegend). Stained BM cells were analyzed in a FACS LSRII instrument and sorted in a FACS Aria3 (Becton Dickinson, San Jose, CA, United States). FlowJo software (Tree Star, Inc., Ashland, OR, United States) was used to analyze and display the data.

Competitive repopulation {#s3-3}
------------------------

BM cells from WT, *5A3*^*+/del*^, *Gata2*^*+/−*^, *Gata2*^*+/−*^*5A3*^*+/del*^ mice on a C57BL/6J background (CD45.2) were used as donor cells. Competitor cells were isolated from 8- to 12-week-old BoyJ mice (CD45.1). Recipient F1 hybrid mice from a cross between C57BL/6J and BoyJ mice (CD45.1 + CD45.2) were at least 8 weeks old at the time of lethal irradiation (9.5 Gy from a cesium source delivered in split dose 3 hr apart). After irradiation, the cells were injected via the tail vein of recipient mice. For evaluation of the competitiveness of whole BM, we injected 10^6^ whole BM cells at a 1:1 or 1:2 donor to competitor ratio. To evaluate the repopulating potential of purified CD150^hi^-HSC, we injected 15 CD150^hi^-HSC sorted from 8- to 12-week-old WT and *5A3*^*+/del*^ mice together with 2.5 × 10^5^ BM competitor cells into lethally irradiated recipients.

Blood was obtained from recipient mice every 30 days beginning 1 month after transplant, and cells were stained with Alexa Fluor 700 CD45.2 (104), PE-Cy7 CD45.1 (A20), PacBlue B220 (RA3-6B2), FITC CD4 (GK1.5), FITC CD8 (53-6.7), PE Mac-1 (M1/70), and PE Gr-1 (RB6-8C5) to determine the percent donor cell contribution to myeloid and B and T lymphoid lineages. Primary recipient mice were euthanized 6 months after transplantation, BM were isolated from the tibiae and femur, and 2 × 10^6^ BM cells were injected into secondary recipients to test serial repopulation potential. To determine the contribution of donor-derived cells in the K^+^L^−^S^+^ compartment, BM cells were stained with V450 CD45.2 (104), APC-780 CD45.1 (A20), PE B220 (RA3-6B2), PE CD8 (53-6.7), PE Gr-1 (RB6-8C5), PE CD3 (17A2), PE Ter119 (TER-119), PE-Cy7 c-kit (2B8), and APC Sca-1 (E13-161.7). Secondary recipients were analyzed as in the primary recipients.

Methylcellulose colony assays {#s3-4}
-----------------------------

CD150^hi^-HSC, CD150^lo^-HSC, and CD150^neg^-MPP were isolated as described above, and 100 cells were seeded into methylcellulose medium as described ([@bib29]). Colonies were counted on day 7, and the entire contents of a methylcellulose culture from an individual plate were then flushed out using phosphate-buffered saline and counted in a hemocytometer. Cells were also spun in a Cytospin 3 Cytocentrifuge (Shandon/Thermo Fisher Scientific, Waltham, MA, United States) at 400 rpm for 8 min, and differential cell counting and morphological analysis performed after Wright-Giemsa staining.

RNA isolation and expression {#s3-5}
----------------------------

CD150^hi^-HSC, CD150^lo^-HSC, and CD150^neg^-MPP were sorted as above into 500 µl of TRIzol reagent (Life Technologies, Grand Island, NY, United States). RNA was isolated according to manufacturer\'s instructions and precipitated with the addition of glycogen (New England BioLabs, Ipswich, MA, United States). The RNA was then treated with DNAse 1 (Ambion, Austin, TX, United States) and purified with the RNeasy MinElute Cleanup Kit (Qiagen, Valencia, CA, United States).

For TaqMan analysis, reverse transcription was carried out using the High Capacity RNA-to-cDNA Master Mix (Life Technologies). Relative quantification of gene expression was determined by performing quantitative real-time PCR using the following TaqMan Gene Expression Assays (Applied Biosystems): *Armc10* (Mm03011576_g1), *Mll5* (Mm01129502_g1), *Napepld* (Mm00724596_m1), *Orc5* (Mm00457242_m1), *Psmc2* (Mm00803207_m1), *Dnajc2* (*Mm00494389_m1*)*, Pmpcb* (*Mm01138654_m1*)*,* *Srpk2* (*Mm00486413_m1*)*, Fbxl13* (*Mm00622025_m1*)*, Lrrc17* (*Mm01167263_m1*)*, Slc26a5* (*Mm00446145_m1*)*, Reln* (*Mm00465200_m1*)*, Lhfpl3* (*Mm03038441_m1*), and *Gapdh* (Mm99999915_g1) with the TaqMan Gene Expression Master Mix (ABI). PCR reactions were performed on an ABI 7900HT Real-Time PCR System (Applied Biosystems, Foster City, CA, United States) with the Taqman Gene Expression Master Mix (Applied Biosystems) according to manufacturer\'s instructions. PCR cycling conditions were 2 min at 50°C and 10 min at 95°C, followed by 40 cycles of 15 s at 95°C and 1 min at 60°C. All reactions were carried out in triplicate, and target quantities were determined using a relative standard curve. The amounts of target were normalized to the endogenous control gene *Gapdh* and compared with the corresponding WT BM (calibrator sample) to determine relative fold differences.

For RNA-Seq analysis, total RNA (10 ng) was converted into double-stranded cDNA using the Ovation RNA Amplification System V2 (NuGen, San Carlo, CA, United States) per manufacturer\'s recommendations. The amplified cDNA products were then used to generate RNA-seq libraries using the TruSeq RNA Sample Preparation Kit v2 reagents (Illumina, San Diego, CA, United States) per manufacturer\'s instructions, with 10 PCR amplification cycles. Library quality and quantity were assessed by the Agilent DNA1000 Chip (Agilent, Santa Clara, CA, United States) and qPCR (Kappa Biosystems Inc, Woburn, MA, United States). 10 pM of each library was sequenced using Illumina SBS chemistry at 2 × 100 bp reads on the HiSeq2000 (Illumina, San Diego, CA, United States).

The RNA-Seq paired-end reads were mapped to the mouse mm9 genome using an in-house mapping and quality assessment pipeline ([@bib56]). The expression of each gene was estimated by the mean coverage of the highest covered coding exon. Genes with low-expression level (\<10) across all samples were filtered out, followed by quantile normalization. Differential expression analysis was performed using limma ([@bib45]) with estimation of false discovery rate ([@bib5]). GSEA ([@bib47], [@bib48]) was used to assess pathway enrichment.

ATP quantification {#s3-6}
------------------

HSC and MPP were sorted into phosphate buffered saline (PBS), and 600 CD150^hi^-HSC, 1000 CD150^lo^-HSC, and 1000 CD150^neg^-MPP were aliquoted into a well of a 96-well plate in triplicate. ATP was quantified using the CellTiter-Glo Luminescent Cell Viability Assay (Promega, Madison, WI, United States) following manufacturer\'s recommendations. Illumination was quantified with a Synergy 2 (Biotek, Winooski, VT, United States).

Metabolic studies {#s3-7}
-----------------

For flow cytometric analysis of ROS levels and membrane potential in CD150^hi^-HSC, CD150^lo^-HSC, and CD150^neg^-MPP, BM cells were isolated and enriched for c-kit positive cells as described. c-kit positive cells were stained with an unconjugated cocktail of purified antibodies including B220 (RA3-6B2), CD8 (53-6.7), Gr-1 (RB6-8C5), CD3 (17A2), Ter119 (TER-119), and CD41 (MWReg30) from BioLegend, followed by PECy-5 IgG GOAT anti-RAT pAb (HI47) antibody from Molecular Probes and IgG from rat serum (I4131 Sigma). After incubation with 50 nM CellROX Orange Reagent (Molecular Probes) or 20 nM MitoTracker Orange CMTMRos (Molecular Probes, Eugene, OR, United States) for 30 min at 37°C in IMDM, cells were washed and stained with 7-amino-actinomycin D, PE-Cy7 c-kit (2B8), PacBlue Sca-1 (E13-161.7), PE-Cy5 CD48 (HM48-1), and APC CD150 (TC15-12F12.2) from BioLegend.

The OCR was analyzed in an XF96 extracellular flux analyzer following manufacturer\'s protocol (Seahorse Biosciences, Billerica, MA, United States). Freshly isolated K^+^L^−^S^+^ cells and K^+^L^−^S^−^ cells were cultured in StemSpan serum-free medium (STEMCELL Technologies, Vancouver, Canada) supplemented with SCF (100 ng/ml) and Tpo (100 ng/ml), while freshly isolated thymic cells and B-220^+^ splenic cells were cultured in RPMI medium 1640 supplemented with 10% fetal calf serum and incubated at 37° in a humidified atmosphere containing 8% CO~2~ for 12--15 hr. Cells were then washed three times with Mito Stress Media (XF base media supplemented with glucose \[3 mg/ml\], sodium pyruvate \[1 mM\], and Glutamax \[2 mM\] adjusted to a pH = 7.4) and seeded in XF96 microplates coated with poly-L-lysine (Sigma). 60000 K^+^L^−^S^+^ cells, 100000 K^+^L^−^S^−^ cells, 200000 thymic cells, and 200000 B220^+^ splenic cells were plated per well, respectively. K^+^L^−^S^+^ and K^+^L^−^S^−^ cells were stimulated with SCF (100 ng/ml) and Tpo (100 ng/ml), while thymic cells were stimulated with interleukin (IL)-2 (20 ng/ml) and IL-7 (10 ng/ml) and B-220^+^ splenic cells were stimulated with IL-7 (10 ng/ml) and maintained in a non-CO~2~ incubator for 1 hr before the assay. Five baseline recordings were made, followed by sequential injection of Oligomycin (Sigma), Carbonyl Cyanide 4-(trifluoromethoxy)phenylhydrazone (Sigma), and a combination of Antimycin A (Sigma) and Rotenone (Sigma) to determine the mitochondrial respiration rate under various conditions.

Statistical analysis {#s3-8}
--------------------

Data are presented as mean values ±SEM unless stated otherwise. Statistical significance was determined by performing two-tailed Student\'s *t*-tests.

Antibodies for flow cytometry of CLP cells {#s3-9}
------------------------------------------

CLP were identified and evaluated by flow cytometry by staining with a lineage cocktail of PE-conjugated antibodies including B220 (RA3-6B2), CD8 (53-6.7), Gr-1 (RB6-8C5), CD3 (17A2), and Ter119 (TER-119), as well as APC-750 c-kit (2B8), PacBlue Sca-1 (E13-161.7), APC IL-7Rα (A7R34) and biotin Flk2 (A2F10), and a streptavidin PE-Cy7 conjugate (BioLegend).

BrdU staining {#s3-10}
-------------

Mice received an initial intraperitoneal injection of BrdU (Sigma--Aldrich, 1 mg/6 g mouse weight) and were then maintained on 1.0 mg/ml BrdU in the drinking water 24 hr prior to sacrifice. To measure BrdU incorporation, BM cells were enriched for c-kit positive cells using c-kit antibody-conjugated microbeads (Miltenyi). Enriched BM cells were pre-incubated with purified CD16/32 (2.4G2), followed by staining with a lineage cocktail of PE-conjugated antibodies including B220 (RA3-6B2), CD8 (53-6.7), Gr-1 (RB6-8C5), CD3 (17A2), Ter119 (TER-119), as well as PECy7 c-kit (2B8) and PacBlue Sca-1 (E13-161.7) (BioLegend). BrdU incorporation was then assayed according to manufacturer\'s instructions of the APC BrdU Flow Kit (BD Pharmingen, San Jose, CA, United States).

NHS-biotin staining {#s3-11}
-------------------

NHS-biotin (EZ-Link Sulfo-NHS-LC-LC-biotin; Life Technologies) was dissolved at 10 mg/ml in normal saline and injected into mice intravenously via the tail vein at 1 mg/6 g mouse weight. To assess biotin dilution in the HSC subpopulations, BM cells were enriched for c-kit positive cells using c-kit antibody-conjugated microbeads (Miltenyi). Enriched cells were pre-incubated with purified CD16/32 (2.4G2), followed by staining with a lineage cocktail of PE-conjugated antibodies including B220 (RA3-6B2), CD8 (53-6.7), Gr-1 (RB6-8C5), CD3 (17A2), Ter119 (TER-119), CD41 (MWReg30), and CD48 (HM48-1), as well as PerCP/Cy5.5 c-kit (2B8), PacBlue Sca-1 (E13-161.7), APC CD150 (TC15-12F12.2), and PECy-7-conjugated Streptavidin (BioLegend).
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Major dataset {#s5-1}
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The following dataset was generated:

Wong JC, Weinfurtner KM, Alzamora M, Kogan SC, Burgess MR, Zhang Y, Nakitandwe J, Ma J, Cheng J, Chen S, Ho TT, Flach J, Reynaud D, Passegue E, Downing JR, Shannon K, 2015,Data from: Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis,<http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE72811>,Available at Gene Expression Omnibus (GEO) with the accession number GSE72811.
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eLife posts the editorial decision letter and author response on a selection of the published articles (subject to the approval of the authors). An edited version of the letter sent to the authors after peer review is shown, indicating the substantive concerns or comments; minor concerns are not usually shown. Reviewers have the opportunity to discuss the decision before the letter is sent (see [review process](http://elifesciences.org/review-process)). Similarly, the author response typically shows only responses to the major concerns raised by the reviewers.

Thank you for submitting your work entitled "Functional evidence implicating chromosome 7q22 haploinsufficiency in myelodysplastic syndrome pathogenesis" for peer review at *eLife*. Your submission has been favorably evaluated by Fiona Watt (Senior editor) and three reviewers, one of whom, Chi Dang, is a member of our Board of Reviewing Editors.

The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.

Summary:

The manuscript by Wong et al. reports an intriguing mouse model of human 7q deletion, *5A3(+/del)* (termed *5A3del*, herein), which is associated with myelodysplastic syndrome (MDS). The mice were smaller in size than their wild-type (WT) counterparts. They documented defects of the *5A3del* hematopoietic stem cell (HSC) KLS-CD150hi cells, which were relatively increased in mutant mice as compared with WT mice. These findings indicate that there is a relative expansion of these HSC pools along with the finding that common myeloid progenitors were increased. The granulocyte-monocyte progenitors were decreased. The *5A3del* HSCs were also diminished in lymphoid progenitors. The authors further characterize mutant versus WT HSCs in reconstitution and transplant models, which all support defects seen in human MDS. However, similar to other mouse models of MDS-associated gene mutations, their mice do not display the hallmarks of MDS; namely, cytopenia, dysplasia, or transformation to AML were not observed. Convincing evidence is provided that there is a cell-autonomous shift in lineage bias of HSCs towards myeloid differentiation. Models were used to study aging HSCs and the authors uncovered a myeloid skewing of *5A3del* HSCs versus WT HSCs. Further, gene expression analysis indicates that genes involved in oxidative phosphorylation (OXPHOS) were diminished. Direct measurements also revealed elevated reactive oxygen species (ROS) levels in aging mutant HSCs. Intriguingly, N-acetylcysteine did not rescue the hematopoietic defects of mutant HSCs. Overall, the model generated appears to recapitulate human MDS associated with chromosome 7q deletion. The finding on alterations of OXPHOS could open up a new avenue of research to further our understanding of the pathogenesis of MDS. The manuscript in its current form, however, did not relate the phenotypic changes with genes that are involved by chromosome 7 deletion. Hence, the mechanistic insight provided by the model lacks depth. Nonetheless, this is an important study of the hematologic consequences of heterozygous inactivation of the 7q22 common deleted region defined for del(7q) MDS.

Essential revisions:

For readers who are less familiar with the genetic architecture of 7q deletions in myeloid malignancies, it would be helpful to provide a broader discussion (in the Introduction or Discussion) of the critical genes on 7q now that a number have been identified that are recurrently mutated. Listing the genes that are mutated, and the frequency of 7q22 loss in the absence of some/all of these genes would be helpful to understand how the 7q22 interval cooperates with other 7q genes and the expected phenotype of the 7q22 deletion in isolation.

Specifically, for [Figure 1](#fig1){ref-type="fig"}, it is suggested that the authors include a schematic showing the commonly deleted regions on human chromosome 7. This will help readers place the current work in context.

For example, whether *EZH2* alterations have been linked to changes in OXPHOS gene expression was not addressed and could be briefly discussed. Given the finding about OXPHOS genes and ROS, ultrastructural analysis of the HSCs for changes in mitochondrial structure might be instructive but optional for this Short Report format.

The elevated CD150 hi population and the altered OxPhos expression raises the question of the state of quiescence of the HSCs. The manuscript notes unchanged BrdU incorporation (data not shown). It would be helpful to show a cell cycle analysis of the stem cell population if possible.

10.7554/eLife.07839.010

Author response

*For readers who are less familiar with the genetic architecture of 7q deletions in myeloid malignancies, it would be helpful to provide a broader discussion (in the Introduction or Discussion) of the critical genes on 7q now that a number have been identified that are recurrently mutated. Listing the genes that are mutated, and the frequency of 7q22 loss in the absence of some/all of these genes would be helpful to understand how the 7q22 interval cooperates with other 7q genes and the expected phenotype of the 7q22 deletion in isolation*.

*Specifically, for* [*Figure 1*](#fig1){ref-type="fig"}*, it is suggested that the authors include a schematic showing the commonly deleted regions on human chromosome 7. This will help readers place the current work in context*.

These are excellent suggestions that speak to the central point that the DNA segment that we used chromosome engineering to excise is of interest because of its strong association with myeloid malignances, particularly myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML). We modified the Introduction and [Figure 1](#fig1){ref-type="fig"} to underscore this point and to concisely summarize the current state of knowledge regarding 7q genes within and outside the relevant 7q22/5A3 interval mutated in MDS and AML. The revised text appears in the second paragraph of the Introduction, and [Figure 1A](#fig1){ref-type="fig"} now presents a diagram of human chromosome 7q with genes implicated as candidate myeloid tumor suppressors shown in italics above, and commonly deleted segments indicated with brackets immediately below. The legend to [Figure 1](#fig1){ref-type="fig"} has been revised. Importantly, targeted and genome-wide sequencing of MDS and AML specimens with monosomy 7 (-7) or 7q deletions \[del(7q)\] have revealed a remarkably low incidence of "second hit" mutations resulting in biallelic inactivation of any 7q gene with the exception of *EZH2,* which is only mutated in a small minority of cases.

*For example, whether EZH2 alterations have been linked to changes in OXPHOS gene expression was not addressed and could be briefly discussed. Given the finding about OXPHOS genes and ROS, ultrastructural analysis of the HSCs for changes in mitochondrial structure might be instructive but optional for this Short Report format*.

This is a good question as *EZH2* is a known myeloid TSG located at 7q36, which is distal to the 7q22*/5A3* CDS that we deleted (see revised [Figure 1A](#fig1){ref-type="fig"}). Since many patients with MDS have monosomy 7 or large 7q deletions, it is possible that loss of *EZH2* and 7q22 genes cooperate to deregulate OXPHOS gene expression. We searched the literature, but did not find any studies linking *EZH2* mutations to abnormal OXPHOS gene expression. If the reviewers are aware of work addressing this question, we would be glad to cite it. We agree that pursuing the relationship of 7q deletions to OXPHOS gene expression is an interesting topic for further investigation, particularly given the transcriptional abnormalities in *5A3* HSC and evidence implicating OXPHOS in HSC homeostasis and aging. Interesting, two genes within the 7q22/5A3 deleted interval (*Pmpcb* and *Armc10),* encode proteins involved in mitochondrial quality control (see last paragraph of subsection "Changes in Gene Expression and Metabolic Activities in 5A3+/del Hematopoietic Cells").

*The elevated CD150 hi population and the altered OxPhos expression raises the question of the state of quiescence of the HSCs. The manuscript notes unchanged BrdU incorporation (data not shown). It would be helpful to show a cell cycle analysis of the stem cell population if possible*.

Thank you for this suggestion. We added [Figure 2--figure supplement 1](#fig2s1){ref-type="fig"} presenting these data. Specifically, we evaluated BrdU incorporation over a 24 hour time course, and also assessed cell division over 6 days by labeling cells with a N-hydroxysulfosuccinimide biotin derivative and quantitating the reduction in this label.

[^1]: Celgene Corporation, San Francisco, United States.
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